Table 4.

Comparison of detection of SARS-CoV-2 in saliva using the TaqPath and in concurrently collected nasopharyngeal swab using an FDA EUA high sensitivity testing platform, Roche COBAS 6800.

Sample Number	Nasopharyngeal Swab(Roche cobas 6800)				Saliva(SalivaClear)
	ORF1ab	E gene	Internal Control	Result	MS2	N gene	ORF1ab	S gene	RP	Result
1	29·24	30·12	33·02	POS	25·66	20·08	19·59	20·13	22·16	POS
2	15·39	15·76	33·43	POS	25·37	20·51	19·81	20·68	23·44	POS
3	18·05	18·29	33·43	POS	25·66	19·97	19·65	20·46	23·04	POS
4	30·58	31·6	32·95	POS	25·54	20·64	20·29	20·9	22·63	POS
5	18·02	18·31	33·48	POS	25·34	19·87	19·54	19·98	22·29	POS
6	30·11	31·14	32·98	POS	25·38	19·58	19·34	19·79	22·23	POS
7	15·49	15·81	33·58	POS	26·02	19·45	19·52	20·10	22·41	POS
8	34·8	37·43	33·04	POS	25·59	20·17	19·89	20·38	22·57	POS
9	24·6	25·09	32·75	POS	25·45	19·69	19·17	19·82	22·09	POS
10	24·99	25·46	32·96	POS	25·51	19·99	19·63	20·05	22·25	POS
11	33·98	35·83	33·17	POS	25·19	22·47	21·97	22·3	26·19	POS
12	23·3	23·73	33·12	POS	24·95	22·16	21·78	22·22	26·61	POS
13	35·71	37·09	33·3	POS	25·43	22·78	22·58	23·04	27·41	POS
14	27·85	28·33	32·85	POS	25·07	21·89	21·82	21·84	26·80	POS
15	33·66	34·95	33·25	POS	28·28	28·6	29·15	ND	19·72	POS
16	32·59	34·74	34·44	POS	27·61	27·59	28·08	ND	19·46	POS
17	34·73	37·93	33·41	POS	26·34	28·34	28·54	ND	20·28	POS
18	33·2	34·77	33·22	POS	28·57	28·61	29·53	ND	19·91	POS
19	32·43	34·75	33·11	POS	26·40	27·68	28·00	ND	20·80	POS
20	31·78	33·83	35·54	POS	26·73	28·43	28·31	ND	19·77	POS
21–120	ND	ND	33·60	NEG	26·64	ND	ND	ND	24·07	NEG

POS – positive; ND – not detected; NEG – negative.